STOCK TITAN
  1. Home
  2. News
  3. ZYXI

Zynex Inc - ZYXI STOCK NEWS

Welcome to our dedicated news page for Zynex (Ticker: ZYXI), a resource for investors and traders seeking the latest updates and insights on Zynex.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zynex's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zynex's position in the market.

News
Zynex Sets First Quarter 2024 Earnings Call
Rhea-AI Summary
Zynex, Inc. (NASDAQ: ZYXI) will host an earnings call on April 30, 2024, to discuss its financial results for the first quarter of 2024. The call will cover the company's performance in manufacturing and selling non-invasive medical devices for pain management, rehabilitation, and patient monitoring.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Zynex Earns Prestigious 2024 Top Workplaces USA Employer Recognition Award
Rhea-AI Summary
Zynex, Inc. (NASDAQ: ZYXI) has been awarded the prestigious 2024 Top Workplaces USA award, highlighting their commitment to a people-first workplace culture. The company's dedication to excellence and collaboration has led to this national recognition, showcasing their exceptional workplace environment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
none
-
News
Zynex Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Zynex Inc. reports a 17% increase in FY 2023 revenue to $184.3 million, announces a $20 million stock repurchase plan. The company achieved record orders, increased cash flow, and net income amidst a challenging Q4. Management expects solid growth in 2024 through new products and revenue streams.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.29%
Tags
earnings
News
Zynex Sets Fourth Quarter and Full Year 2023 Earnings Call
Rhea-AI Summary
Zynex, Inc. (ZYXI) will host a conference call on February 29, 2024, to discuss its financial results for Q4 and full year 2023. The company specializes in non-invasive medical devices for pain management and rehabilitation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
earnings
-
News
Zynex Introduces New Products
Rhea-AI Summary
Zynex, Inc. (ZYXI) launches two new therapy products, the Zynex Pro Hybrid LSO and Zynex DynaComp Cold Compression, aimed at pain management and rehabilitation. The innovative devices offer versatile solutions for individual patient needs, combining comfort, support, and portability for faster recovery and enhanced daily activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
none
-
News
Zynex Receives FDA Clearance for its Next Generation NMES Device
Rhea-AI Summary
Zynex, Inc. receives FDA clearance for the next generation M-Wave Neuromuscular Electrical Stimulation device, replacing the E-Wave. The M-Wave aims to improve patient management of neuromuscular conditions with advanced features and user-friendly design, allowing for customizable treatments in clinical and home settings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.62%
Tags
clinical trial
News
Zynex Recognized in Top 25 Medical Device Companies for 2024
Rhea-AI Summary
Zynex, Inc. (NASDAQ: ZYXI) has been recognized as 9th amongst the Top 25 Medical Device Companies for 2024 by The Healthcare Technology Report. The company specializes in non-invasive medical devices for pain management, rehabilitation, and patient monitoring. CEO Thomas Sandgaard expressed his pleasure at the recognition, emphasizing the company's influence and success in the medical device space.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
none
-
News
Zynex to Participate at the Needham Annual Growth Conference
Rhea-AI Summary
Zynex, Inc. (NASDAQ: ZYXI) to participate in Needham Annual Growth Conference, offering innovative medical technology for pain management and patient monitoring.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.87%
Tags
conferences
-
News
Zynex Ranked in Forbes List of "America's Most Successful Small-Cap Companies 2024"
Rhea-AI Summary
Zynex, Inc. (NASDAQ: ZYXI) has been ranked within Forbes' list of America's Most Successful Small-Cap Companies for 2024, marking the fourth consecutive year the company has received this honor. The rankings are based on factors such as earnings growth, sales growth, return on equity, and total stock return for the trailing twelve months and over the last five years. Zynex's CEO, Thomas Sandgaard, expressed gratitude for the recognition and emphasized the company's commitment to providing non-invasive patient solutions for consistent revenue and profitability growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.65%
Tags
none
News
Zynex Submits FDA Application for its Next Generation NMES Device
Rhea-AI Summary
Zynex, Inc. (NASDAQ: ZYXI) announces the submission of a 510(k) application to the FDA for the M-Wave Neuromuscular Electrical Stimulation device. The M-Wave is set to replace the E-Wave, providing more advanced features and a user-friendly design for patients dealing with neuromuscular conditions. This submission demonstrates Zynex Medical's commitment to delivering cutting-edge medical devices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
none
Stock ZYXI logo
Zynex Inc

Nasdaq:ZYXI

ZYXI Rankings

#3261 Ranked by Market Cap
#3699 Ranked by Stock Gains
N/A Ranked by Dividends

ZYXI Stock Data

380.28M
15.72M
51.14%
31.25%
18%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Englewood

About ZYXI

zynex, inc. founded in 1996, engineers, manufactures and markets neuro-diagnostics, stroke rehabilitation, pain management and cardiac monitoring devices within three subsidiaries. zynex medical is a provider of electrotherapy products for home use. zynex monitoring solutions develops products for cardiac monitoring for use in hospitals. zynex neurodiagnostics develops devices for emg and eeg diagnostic applications within neurology disciplines. zynex medical's product line is fully developed, fda/ce cleared, commercially sold, and has been developed to uphold the company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. zynex monitoring solutions and zynex neurodiagnostics are currently both in the development stages without any significant revenues.